<?xml version="1.0" encoding="utf-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD AAFP JATS Archival DTD v1.0 20141031//EN" "aafp-jats-archival1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" CME="yes" article-type="feature" dtd-version="1.0" tool-inside="no" xml:lang="en">
<front>
<journal-meta>
<journal-id/>
<journal-title-group>
<journal-title>American Family Physician</journal-title>
<abbrev-journal-title>AFP</abbrev-journal-title>
</journal-title-group>











<issn pub-type="ppub"/>
<issn publication-format="electronic">1532-0650</issn>
<issn publication-format="print">0002-838X</issn>
<publisher>
<publisher-name>American Academy of Family Physicians</publisher-name>
<publisher-loc>
<addr-line>Publications Division</addr-line>
<addr-line>11400 Tomahawk Creek Parkway</addr-line>
<addr-line>Leawood, KS 66211-2672</addr-line>
<phone>800-274-2237</phone>
</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid"/>
<article-categories>
<subj-group subj-group-type="article-type">
<subject>Articles</subject>
</subj-group>



</article-categories>
<title-group>
<article-title>Pharmacologic Treatment of Depression</article-title>
<alt-title>pharmacologic treatment of depression</alt-title>
</title-group>



<author-notes>
<title>Author Information</title>
<fn>
<p>HEATHER KOVICH, MD, is program director of the Shiprock-University of New Mexico Family Medicine Residency and a family physician at the Northern Navajo Medical Center, Shiprock.</p>
</fn>
<fn>
<p>WILLIAM KIM, MS, MD, is associate program director of the Shiprock-University of New Mexico Family Medicine Residency.</p>
</fn>
<fn>
<p>ANTHONY M. QUASTE, PharmD, USPHS, is a clinical pharmacist at Indian Health Service, Northern Navajo Medical Center.</p>
</fn>
<fn>
<p>Author disclosure: No relevant financial relationships.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>02</month>
<year>2023</year>
</pub-date>
<volume>107</volume>
<issue>2</issue>
<fpage>173</fpage>
<lpage>181</lpage>
<permissions>
<copyright-year>2023</copyright-year>
<copyright-holder>American Academy of Family Physicians</copyright-holder>
</permissions>


<custom-meta-group>
<custom-meta>
<meta-name>byline</meta-name>
<meta-value>HEATHER KOVICH, MD, Shiprock-University of New Mexico Family Medicine Residency Program and Northern Navajo Medical Center, Shiprock, New Mexico</meta-value>
</custom-meta>
<custom-meta>
<meta-name>byline</meta-name>
<meta-value>WILLIAM KIM, MS, MD, Shiprock-University of New Mexico Family Medicine Residency Program, Shiprock, New Mexico</meta-value>
</custom-meta>
<custom-meta>
<meta-name>byline</meta-name>
<meta-value>ANTHONY M. QUASTE, PharmD, USPHS, Northern Navajo Medical Center, Shiprock, New Mexico</meta-value>
</custom-meta>
</custom-meta-group>






<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Kovich</surname>
<given-names>Heather</given-names>
</name>
<degrees>MD</degrees>
<bio>
<p>HEATHER KOVICH, MD, is program director of the Shiprock-University of New Mexico Family Medicine Residency and a family physician at the Northern Navajo Medical Center, Shiprock.</p>
</bio>
</contrib>
<contrib contrib-type="author">
<name name-style="western">
<surname>Kim</surname>
<given-names>William</given-names>
</name>
<degrees>MS, MD</degrees>
<bio>
<p>WILLIAM KIM, MS, MD, is associate program director of the Shiprock-University of New Mexico Family Medicine Residency.</p>
</bio>
</contrib>
<contrib contrib-type="author">
<name name-style="western">
<surname>Quaste</surname>
<given-names>Anthony M.</given-names>
</name>
<degrees>PharmD, USPHS</degrees>
<bio>
<p>ANTHONY M. QUASTE, PharmD, USPHS, is a clinical pharmacist at Indian Health Service, Northern Navajo Medical Center.</p>
</bio>
</contrib>
</contrib-group>
<abstract abstract-type="dek">
<p>The prevalence of depression and the use of antidepressant medications have risen steadily in the United States over the past three decades. Antidepressants are the most commonly prescribed medications for U.S. adults 20 to 59 years of age. Second-generation antidepressants (e.g., selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin modulators, atypical antidepressants) are first-line therapy for depression. Psychotherapy, including cognitive behavior therapy and other types of individual and group therapy, is also a first-line treatment. The combination of medication and psychotherapy is preferred for severe depression. Treatment history, comorbidities, costs, and risk of adverse effects should be considered when choosing an antidepressant medication. Although many patients use antidepressants indefinitely, few studies have examined safety and effectiveness beyond two years. There is an increased risk of relapse or recurrence of depressive symptoms when an antidepressant is discontinued, compared with continued use. Gradually tapering the dosage while concurrently providing cognitive behavior therapy can decrease this risk. High-quality evidence on antidepressant use in pregnancy is lacking. Depression and use of antidepressants are both associated with preterm birth. (Am Fam Physician. 2023; 107(2): 173–181. Copyright © 2023 American Academy of Family Physicians.)</p>
</abstract>
<abstract>
<p>The prevalence of depression and the use of antidepressant medications have risen steadily in the United States over the past three decades. Antidepressants are the most commonly prescribed medications for U.S. adults 20 to 59 years of age. Second-generation antidepressants (e.g., selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin modulators, atypical antidepressants) are first-line therapy for depression. Psychotherapy, including cognitive behavior therapy and other types of individual and group therapy, is also a first-line treatment. The combination of medication and psychotherapy is preferred for severe depression. Treatment history, comorbidities, costs, and risk of adverse effects should be considered when choosing an antidepressant medication. Although many patients use antidepressants indefinitely, few studies have examined safety and effectiveness beyond two years. There is an increased risk of relapse or recurrence of depressive symptoms when an antidepressant is discontinued, compared with continued use. Gradually tapering the dosage while concurrently providing cognitive behavior therapy can decrease this risk. High-quality evidence on antidepressant use in pregnancy is lacking. Depression and use of antidepressants are both associated with preterm birth. </p>
</abstract>
</article-meta>
</front>
<body>
<p>The use of antidepressant medications in the United States has increased fivefold since the introduction of selective serotonin reuptake inhibitors (SSRIs) in the late 1980s.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b1">1</xref>,<xref ref-type="bibr" rid="afp20230200p173-b2">2</xref>
</sup> Between 2015 and 2018, the percentage of U.S. adults who reported taking an antidepressant medication in the past 30 days was 13.2%, compared with 2.4% between 1988 and 1994.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b1">1</xref>,<xref ref-type="bibr" rid="afp20230200p173-b2">2</xref>
</sup> </p>
<table-wrap id="afp20230200p173-ut3" orientation="portrait" position="float">
<caption>
<title>WHAT'S NEW ON THIS TOPIC</title>
<p>
<bold>Pharmacologic Treatment of Depression</bold>
</p>
</caption>
<table>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Between 2015 and 2018, the percentage of U.S. adults who reported taking an antidepressant medication in the past 30 days was 13.2%, compared with 2.4% between 1988 and 1994.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Modest evidence shows that escitalopram, mirtazapine, paroxetine, venlafaxine, and amitriptyline are the most effective antidepressants for reducing acute depressive symptoms by greater than 50% at eight weeks.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">A 2021 network meta-analysis demonstrated a low risk of ventricular arrhythmia or sudden cardiac death in those taking selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or tricyclic antidepressants.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Typical symptoms of antidepressant discontinuation syndrome can be described using the FINISH mnemonic (flulike symptoms, insomnia, nausea, imbalance, sensory disturbances, hyperarousal).</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap content-type="sort" id="afp20230200p173-ut1" orientation="portrait" position="float">
<caption>
<title>SORT: KEY RECOMMENDATIONS FOR PRACTICE</title>
</caption>
<table>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Clinical recommendation</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="middle">
<bold>Evidence rating</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Comments</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="sort" rid="afp20230200p173-sort1">In the primary care setting, antidepressant medication and psychotherapy should be offered for the treatment of depression.</xref>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b17">17</xref>–<xref ref-type="bibr" rid="afp20230200p173-b20">20</xref>
</sup>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<bold>A</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Network meta-analysis, systematic reviews, clinical practice guidelines</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="sort" rid="afp20230200p173-sort2">Second-generation antidepressants, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin modulators, and atypical antidepressants, are recommended first-line medications for the treatment of depression. Choice of medication should be guided by shared decision-making, with consideration of prior treatment and response, comorbidities, costs, and risk of adverse effects.</xref>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b10">10</xref>,<xref ref-type="bibr" rid="afp20230200p173-b16">16</xref>,<xref ref-type="bibr" rid="afp20230200p173-b17">17</xref>
</sup>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<bold>B</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Clinical practice guidelines, systematic reviews</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="sort" rid="afp20230200p173-sort3">When antidepressants are discontinued, the risk of relapse or recurrence of depressive symptoms is higher than when treatment is continued.</xref>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b42">42</xref>–<xref ref-type="bibr" rid="afp20230200p173-b44">44</xref>
</sup>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<bold>A</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Double-blind randomized controlled trial, systematic reviews, meta-analyses</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="sort" rid="afp20230200p173-sort4">When discontinuing antidepressants, cognitive behavior therapy should be used to help prevent relapse and recurrence of depressive symptoms.</xref>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b56">56</xref>
</sup>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<bold>B</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Two studies included in larger meta-analysis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="sort" rid="afp20230200p173-sort5">Pregnant and postpartum patients should be screened for depression.</xref>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b61">61</xref>
</sup>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<bold>B</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Systematic reviews of six clinical trials (n = 11,869) showing decrease in depressive symptoms in patients who are screened, even in the absence of follow-up measures</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="sort" rid="afp20230200p173-sort6A">Fluoxetine and paroxetine should be avoided in older patients.</xref> <xref ref-type="sort" rid="afp20230200p173-sort6B">Recommended alternatives include duloxetine (Cymbalta), sertraline, and escitalopram.</xref>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b77">77</xref>
</sup>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">
<bold>C</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Clinical practice guidelines</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<bold>A</bold> = consistent, good-quality patient-oriented evidence; <bold>B</bold> = inconsistent or limited-quality patient-oriented evidence; <bold>C</bold> = consensus, disease-oriented evidence, usual practice, expert opinion, or case series; For information about the SORT evidence rating system, go to <uri xlink:href="https://www.aafp.org/afpsort">https://www.aafp.org/afpsort</uri>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Antidepressants are the most commonly prescribed medications for U.S. adults 20 to 59 years of age.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b3">3</xref>
</sup> Rates of depression and suicide have increased, primarily among those younger than 25 years.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b4">4</xref>,<xref ref-type="bibr" rid="afp20230200p173-b5">5</xref>
</sup> The percentage of adults 18 to 25 years of age reporting a major depressive episode in the past year doubled from 8.8% in 2005 to 17% in 2020. During the same period, rates among adults 26 years and older increased only slightly from 6.2% to 7.1%.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b6">6</xref>,<xref ref-type="bibr" rid="afp20230200p173-b7">7</xref>
</sup> </p>
<p>The definition of a major depressive episode is based on the <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders</italic>, 5th ed., criteria for major depressive disorder.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b6">6</xref>,<xref ref-type="bibr" rid="afp20230200p173-b8">8</xref>
</sup> Five or more depressive symptoms must be present for at least two weeks, cause distress or functional impairment, and not be due to another medical or psychiatric condition. Symptoms include depressed mood, anhedonia, changes in weight or sleep patterns, fatigue, psychomotor agitation or retardation, feelings of worthlessness or guilt, impaired concentration, and recurrent thoughts of death.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b6">6</xref>,<xref ref-type="bibr" rid="afp20230200p173-b8">8</xref>
</sup> Clinical trials of antidepressants often use major depressive episode as an inclusion criterion. Although most patients with clinician-identified depression do not meet diagnostic criteria for a major depressive episode, many are prescribed antidepressants.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b9">9</xref>
</sup> </p>
<p>Second-generation antidepressants are the most common medications used to treat depression in the United States.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b10">10</xref>
</sup> These include SSRIs (e.g., escitalopram, paroxetine), serotonin-norepinephrine reuptake inhibitors (SNRIs; e.g., duloxetine [Cymbalta], venlafaxine), serotonin modulators (e.g., nefazodone, trazodone), and atypical antidepressants (e.g., bupropion, mirtazapine).</p>
<p>
<h2>Effectiveness</h2>
</p>
<p>Despite thousands of clinical trials, the effectiveness of antidepressants is not well established. High-quality reviews of randomized controlled studies show a statistically significant improvement in depression with use of antidepressant medications.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b11">11</xref>,<xref ref-type="bibr" rid="afp20230200p173-b12">12</xref>
</sup> A 2016 systematic review showed that the number needed to treat for response to treatment or remission is 9 for tricyclic antidepressants, 7 for SSRIs, and 6 for venlafaxine.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b11">11</xref>
</sup> Outcomes of other studies challenge these conclusions, with minimal difference in symptoms between placebo and antidepressants, publication bias favoring effectiveness, and pharmaceutical industry sponsorship of most clinical trials.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b11">11</xref>,<xref ref-type="bibr" rid="afp20230200p173-b13">13</xref>,<xref ref-type="bibr" rid="afp20230200p173-b14">14</xref>
</sup> A recent national survey of adults with depression revealed that those who used antidepressants had no improvement in health-related quality of life at two years of follow-up compared with those who did not use antidepressants.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b15">15</xref>
</sup>
</p>
<p>Psychotherapy (e.g., behavior therapy, cognitive therapy, cognitive behavior therapy, interpersonal psychotherapy, psychodynamic therapy, supportive therapy) is also a first-line treatment for depression.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b16">16</xref>,<xref ref-type="bibr" rid="afp20230200p173-b17">17</xref>
</sup> The effectiveness of psychotherapy is similar to that of antidepressants in the primary care setting (relative risk [RR] = 1.03; 95% CI, 0.88 to 1.22).<sup>
<xref ref-type="bibr" rid="afp20230200p173-b18">18</xref>
</sup> Evidence for cognitive behavior therapy is more robust than for other types of therapy.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b10">10</xref>
</sup> <span id="afp20230200p173-sort1">The combination of psychotherapy and pharmacotherapy may be more effective than either treatment alone for moderate or severe depression and may reduce risk of relapse and recurrence.</span>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b17">17</xref>,<xref ref-type="bibr" rid="afp20230200p173-b19">19</xref>,<xref ref-type="bibr" rid="afp20230200p173-b20">20</xref>
</sup>
</p>
<p>
<h2>Selection of Initial Depression Therapy</h2>
</p>
<p>Guidelines from the United Kingdom's National Institute for Health and Care Excellence recommend against routinely offering medication for mild to moderate depression (defined as a Patient Health Questionnaire-9 score of less than 16). If the patient prefers medication, SSRIs are recommended. Active monitoring, group exercise, and several types of individual and group therapy are recommended as management options. For more severe depression, a combination of individual cognitive behavior therapy and an antidepressant (SSRI or SNRI) is recommended.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b17">17</xref>
</sup>
</p>
<p>
<span id="afp20230200p173-sort2">Shared decision-making should be used when choosing an initial treatment. Prior treatment and response, comorbidities, costs, and risk of adverse effects should be considered. Pharmacogenetic testing, intended to tailor therapy to an individual's genetic variants, has not shown consistent benefit in outcomes or cost-effectiveness.</span>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b21">21</xref>
</sup>
</p>
<p>For the general adult population, treatment should start with a second-generation antidepressant or psychotherapy.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b10">10</xref>,<xref ref-type="bibr" rid="afp20230200p173-b16">16</xref>,<xref ref-type="bibr" rid="afp20230200p173-b17">17</xref>
</sup> If an antidepressant is selected, modest evidence shows that escitalopram, mirtazapine, paroxetine, venlafaxine, and amitriptyline are most effective in reducing depressive symptoms by greater than 50% at eight weeks (odds ratio = 1.19 to 1.96).<sup>
<xref ref-type="bibr" rid="afp20230200p173-b12">12</xref>
</sup>
</p>
<p>
<h2>Adverse Effects</h2>
</p>
<p>Nausea and vomiting were the most commonly reported symptoms leading to antidepressant discontinuation during clinical trials. Patients taking SNRIs have a higher incidence of nausea and vomiting than those taking SSRIs.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b22">22</xref>
</sup> Other common adverse effects across drug classes include sexual adverse effects and weight gain, although these are less likely with bupropion.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b22">22</xref>,<xref ref-type="bibr" rid="afp20230200p173-b23">23</xref>
</sup> </p>
<p>Despite concerns about increased risk of cardiac arrhythmia with SSRIs, a 2021 network meta-analysis demonstrated a low risk of ventricular arrhythmia or sudden cardiac death in those taking SSRIs, SNRIs, or tricyclic antidepressants.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b24">24</xref>
</sup> QT prolongation can occur with these drug classes; therefore, caution should be used when combining them with other medications that cause QT prolongation (e.g., antiemetics, antiarrhythmics, neuroleptics). Bupropion has the lowest risk of QT prolongation in patients at high risk of ventricular arrhythmias. Because of its side effect profile and potential for beneficial antiplatelet activity, sertraline may be preferred for those with ischemic heart disease.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b25">25</xref>
</sup> </p>
<p>Long-term adverse effects should also be considered when prescribing antidepressants. Limited-quality evidence, including a 12-year cohort study, found a correlation between SSRI use and falls (hazard ratio [HR] = 1.48; 95% CI, 1.39 to 1.59); fractures (HR = 1.30; 95% CI, 1.21 to 1.39); and all-cause mortality (HR = 1.38; 95% CI, 1.26 to 1.51).<sup>
<xref ref-type="bibr" rid="afp20230200p173-b26">26</xref>
</sup> </p>
<p>In a review of 21 antidepressants, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine (Trintellix) were most tolerated with less discontinuation of treatment (odds ratio = 0.43 to 0.77).<sup>
<xref ref-type="bibr" rid="afp20230200p173-b12">12</xref>
</sup> Adverse effects associated with antidepressants are summarized in <italic toggle="yes">
<xref ref-type="table" rid="afp20230200p173-t1">Table 1</xref>
</italic>.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b23">23</xref>,<xref ref-type="bibr" rid="afp20230200p173-b27">27</xref>–<xref ref-type="bibr" rid="afp20230200p173-b36">36</xref>
</sup> </p>
<table-wrap id="afp20230200p173-t1" orientation="portrait" position="float">
<caption>
<title>Adverse Effects Associated With Antidepressant Medications</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Adverse effect</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Risk</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Associated medications</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Time to onset</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Evidence</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Gastrointestinal bleeding</td>
<td align="left" colspan="1" rowspan="1" valign="top">Odds ratio = 1.55 (95% CI, 1.35 to 1.78)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SSRIs, especially when used with nonsteroidal anti-inflammatory drugs or antiplatelet drugs; risk mitigated by acid-suppressing medications</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anytime during treatment</td>
<td align="left" colspan="1" rowspan="1" valign="top">Meta-analysis<sup>
<xref ref-type="bibr" rid="afp20230200p173-b27">27</xref>
</sup> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hepatotoxicity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Incidence = 0.5% to 3%</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nefazodone, bupropion, duloxetine (Cymbalta), trazodone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anytime during treatment</td>
<td align="left" colspan="1" rowspan="1" valign="top">Literature review <sup>
<xref ref-type="bibr" rid="afp20230200p173-b28">28</xref>
</sup> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hyponatremia (sodium &lt; 130 mEq per L [130 mmol per L])</td>
<td align="left" colspan="1" rowspan="1" valign="top">Incidence = 0.06% to 2.6%</td>
<td align="left" colspan="1" rowspan="1" valign="top">SSRIs, SNRIs, mirtazapine, TCAs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Within the first month</td>
<td align="left" colspan="1" rowspan="1" valign="top">Literature review <sup>
<xref ref-type="bibr" rid="afp20230200p173-b29">29</xref>
</sup> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Osteoporosis and fractures</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hazard ratio = 1.88 (95% CI, 1.48 to 2.39) for fragility fracture</td>
<td align="left" colspan="1" rowspan="1" valign="top">SSRIs, SNRIs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Over 10 years</td>
<td align="left" colspan="1" rowspan="1" valign="top">Prospective cohort<sup>
<xref ref-type="bibr" rid="afp20230200p173-b30">30</xref>
</sup> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">QT prolongation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dose dependent</td>
<td align="left" colspan="1" rowspan="1" valign="top">Citalopram, escitalopram, amitriptyline<br/>U.S. Food and Drug Administration warns against exceeding recommended dose of citalopram (≤ 60 years of age, 40 mg per day; &gt; 60 years, 20 mg per day)</td>
<td align="left" colspan="1" rowspan="1" valign="top">At initiation<br/>Typically dependent on coexisting risk factors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cross-sectional retrospective studies<sup>
<xref ref-type="bibr" rid="afp20230200p173-b31">31</xref>,<xref ref-type="bibr" rid="afp20230200p173-b32">32</xref>
</sup> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sexual adverse effects</td>
<td align="left" colspan="1" rowspan="1" valign="top">Weighted mean incidence = 40% (95% CI, 28.3 to 52.6) across observational studies</td>
<td align="left" colspan="1" rowspan="1" valign="top">Trend toward increased risk with escitalopram and paroxetine; decreased risk with bupropion</td>
<td align="left" colspan="1" rowspan="1" valign="top">Within the first week</td>
<td align="left" colspan="1" rowspan="1" valign="top">Meta-analysis<sup>
<xref ref-type="bibr" rid="afp20230200p173-b33">33</xref>,<xref ref-type="bibr" rid="afp20230200p173-b34">34</xref>
</sup> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Suicidality</td>
<td align="left" colspan="1" rowspan="1" valign="top">Age-related risk<br/> &lt; 18 years: odds ratio = 2.39 (95% CI, 1.31 to 4.3)<br/> ≥ 18 years: odds ratio = 0.81 (95% CI, 0.51 to 1.2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Duloxetine, fluoxetine, paroxetine, sertraline, venlafaxine</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not defined</td>
<td align="left" colspan="1" rowspan="1" valign="top">Systematic review, meta-analysis of clinical reports<sup>
<xref ref-type="bibr" rid="afp20230200p173-b35">35</xref>
</sup> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Weight gain (&gt; 5%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rate ratio<br/> 1.21 (95% CI, 1.20 to 1.23) for SSRIs<br/> 1.17 (95% CI, 1.13 to 1.21) for SNRIs<br/> 1.16 (95% CI, 1.14 to 1.18) for TCAs</td>
<td align="left" colspan="1" rowspan="1" valign="top">SSRIs, SNRIs, TCAs<br/>Decreased risk with bupropion</td>
<td align="left" colspan="1" rowspan="1" valign="top">Over 10 years (highest risk in first two years)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Population-based cohort study, systematic review<sup>
<xref ref-type="bibr" rid="afp20230200p173-b23">23</xref>,<xref ref-type="bibr" rid="afp20230200p173-b36">36</xref>
</sup> </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.</p>
<p>
<italic toggle="yes">Information from references <sup>
<xref ref-type="bibr" rid="afp20230200p173-b23">23</xref>
</sup> and <sup>
<xref ref-type="bibr" rid="afp20230200p173-b27">27</xref>
</sup>–<sup>
<xref ref-type="bibr" rid="afp20230200p173-b36">36</xref>
</sup>
</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>
<h2>Duration of Treatment</h2>
</p>
<p>The treatment of depression is often described in three phases. The acute phase of six to 12 weeks is intended to induce remission of symptoms and aid in recovery of function. The continuation phase of four to nine months is aimed at reducing relapse (return of symptoms). The maintenance phase is intended to prevent recurrence (a new episode of depression) after one year of treatment.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b10">10</xref>,<xref ref-type="bibr" rid="afp20230200p173-b37">37</xref>
</sup> </p>
<p>Although up to 75% of patients discontinue antidepressant use within six months, others continue indefinitely.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b38">38</xref>
</sup> The increase in antidepressant use over the past 30 years is largely due to longer treatment duration.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b39">39</xref>
</sup> The longer patients are in the maintenance phase, the less often treatment is reviewed by their primary care physicians.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b40">40</xref>
</sup> Few studies have evaluated safety and effectiveness beyond two years.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b41">41</xref>
</sup> </p>
<p>
<span id="afp20230200p173-sort3">Whenever antidepressants are discontinued, there is an increased risk of relapse or recurrence, with the highest risk in the first six months.</span>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b42">42</xref>–<xref ref-type="bibr" rid="afp20230200p173-b44">44</xref>
</sup> Compared with antidepressants, psychotherapy may have a longer duration of benefit and lower rate of relapse after discontinuation.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b15">15</xref>
</sup>
</p>
<p>U.S. guidelines do not specify a duration of treatment for antidepressants.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b10">10</xref>,<xref ref-type="bibr" rid="afp20230200p173-b16">16</xref>
</sup> Canadian guidelines recommend at least six months of treatment and two years or more for those at higher risk of relapse.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b45">45</xref>
</sup> Because each episode of depression adds to a patient's risk of future episodes, indefinite maintenance treatment is often recommended for patients with three or more episodes of depression.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b37">37</xref>
</sup> </p>
<p>
<h2>Discontinuation</h2>
</p>
<p>The <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders</italic>, 5th ed., defines antidepressant discontinuation syndrome as “a set of symptoms that can occur after an abrupt cessation (or marked reduction in dose) of an antidepressant medication that was taken continuously for at least one month.”<sup>
<xref ref-type="bibr" rid="afp20230200p173-b8">8</xref>
</sup> Effects typically manifest within two to four days and can last for several months.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b46">46</xref>
</sup> Typical symptoms can be described using the FINISH mnemonic (flulike symptoms, insomnia, nausea, imbalance, sensory disturbances, hyperarousal).<sup>
<xref ref-type="bibr" rid="afp20230200p173-b47">47</xref>
</sup> Patients should be counseled on symptoms that may occur with abrupt cessation of treatment.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b48">48</xref>
</sup> </p>
<p>Symptoms of antidepressant discontinuation syndrome can be difficult to distinguish from relapse and recurrence. The prevalence of these symptoms varies, but some reviews have found that 50% of patients are affected.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b46">46</xref>
</sup> Regardless of pharmacologic mechanism, the risk of antidepressant discontinuation syndrome is higher for drugs with a shorter half-life <italic toggle="yes">(<xref ref-type="table" rid="afp20230200p173-t2">Table 2</xref>)</italic>.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b49">49</xref>,<xref ref-type="bibr" rid="afp20230200p173-b50">50</xref>
</sup> </p>
<table-wrap id="afp20230200p173-t2" orientation="portrait" position="float">
<caption>
<title>Comparative Risk of Antidepressant Discontinuation Syndrome for Selected Antidepressants</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Antidepressant</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Risk<xref ref-type="table" rid="afp20230200p173-tfn5">*</xref>
</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="2" rowspan="1" valign="top">
<bold>Atypical antidepressant</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Bupropion</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Mirtazapine</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1" valign="top">
<bold>Serotonin-norepinephrine reuptake inhibitor</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Desvenlafaxine (Pristiq)</td>
<td align="left" colspan="1" rowspan="1" valign="top">+++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Venlafaxine</td>
<td align="left" colspan="1" rowspan="1" valign="top">+++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Duloxetine (Cymbalta)</td>
<td align="left" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Milnacipran</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1" valign="top">
<bold>SSRI</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Fluvoxamine</td>
<td align="left" colspan="1" rowspan="1" valign="top">+++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Paroxetine</td>
<td align="left" colspan="1" rowspan="1" valign="top">+++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Citalopram</td>
<td align="left" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Escitalopram</td>
<td align="left" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sertraline</td>
<td align="left" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Fluoxetine</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1" valign="top">
<bold>SSRI/partial 5-HT</bold>
<sub>1A</sub>
<bold>receptor agonist</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Trazodone</td>
<td align="left" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Vortioxetine (Trintellix)</td>
<td align="left" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Vilazodone (Viibryd)</td>
<td align="left" colspan="1" rowspan="1" valign="top">+</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1" valign="top">
<bold>Tricyclic antidepressant</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Imipramine</td>
<td align="left" colspan="1" rowspan="1" valign="top">+++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nortriptyline</td>
<td align="left" colspan="1" rowspan="1" valign="top">+++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Amitriptyline</td>
<td align="left" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Clomipramine</td>
<td align="left" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Desipramine</td>
<td align="left" colspan="1" rowspan="1" valign="top">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Doxepin</td>
<td align="left" colspan="1" rowspan="1" valign="top">++</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>SSRI = selective serotonin reuptake inhibitor; 5-HT = serotonin.</p>
<p>*—High risk = +++; moderate risk = ++; low risk = +.</p>
<p>
<italic toggle="yes">Information from references <sup>
<xref ref-type="bibr" rid="afp20230200p173-b49">49</xref>
</sup> and <sup>
<xref ref-type="bibr" rid="afp20230200p173-b50">50</xref>
</sup>
</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Despite a lack of head-to-head trials, research shows that a slow medication taper of at least 14 days is best practice; a taper of several months may be needed.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b51">51</xref>–<xref ref-type="bibr" rid="afp20230200p173-b54">54</xref>
</sup> Tapering strategies are detailed in <italic toggle="yes">
<xref ref-type="table" rid="afp20230200p173-t3">Table 3</xref>
</italic>.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b51">51</xref>–<xref ref-type="bibr" rid="afp20230200p173-b53">53</xref>
</sup> A dose taper of approximately 25% every four weeks and a faster taper of 12.5% every two weeks are both reasonable strategies. A gradual taper has been shown to result in as few as 5% of patients experiencing discontinuation symptoms.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b55">55</xref>
</sup> <span id="afp20230200p173-sort4">Use of cognitive behavior therapy during the medication taper may help prevent relapse or recurrence.</span>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b56">56</xref>
</sup>
</p>
<table-wrap id="afp20230200p173-t3" orientation="portrait" position="float">
<caption>
<title>Tapering Strategies for Antidepressant Medications</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Strategy</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Description</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="middle">
<bold>Example</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="middle"/>
<th align="left" colspan="2" rowspan="1" valign="middle">
<bold>Comments</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">10% reduction per week</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduce dose every four weeks to match 10% reduction in serotonin transporter occupancy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Citalopram:<br/> 40 mg for four weeks<br/> 20 mg for four weeks<br/> 19 mg for four weeks<br/> 9.1 mg for four weeks<br/> 5.4 mg for four weeks<br/> 3.4 mg for four weeks<br/> 2.3 mg for four weeks<br/> 1.5 mg for four weeks<br/> 0.8 mg for four weeks<br/> 0.37 mg for four weeks</td>
<td align="left" colspan="1" rowspan="1" valign="top"/>
<td align="left" colspan="2" rowspan="1" valign="top">Formulated using pharmacokinetic data but difficult to precisely implement</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Three- to four-month taper</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduce dose by 25% every four weeks or by 12.5% every two weeks</td>
<td align="left" colspan="1" rowspan="1" valign="top">Citalopram:<br/> 40 mg for four weeks<br/> 30 mg for four weeks<br/> 20 mg for four weeks<br/> 15 mg for four weeks<br/> 10 mg for four weeks<br/> 7.5 mg for four weeks<br/> 5 mg for four weeks<br/> 2.5 mg for four weeks</td>
<td align="left" colspan="1" rowspan="1" valign="top"/>
<td align="left" colspan="2" rowspan="1" valign="top">Easier to accomplish in real-world practice, but linear dose decrease may still result in antidepressant discontinuation syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cross taper</td>
<td align="left" colspan="1" rowspan="1" valign="top">Slowly decrease dose of the current medication while increasing dose of the new medication</td>
<td align="left" colspan="1" rowspan="1" valign="top">Citalopram (current medication, 40-mg starting dose):<br/> 30 mg for four weeks<br/> 20 mg for four weeks<br/> 15 mg for four weeks<br/> 10 mg for four weeks<br/> 7.5 mg for four weeks<br/> 5 mg for four weeks<br/> 2.5 mg for four weeks</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sertraline (new medication):<br/> 12.5 mg for four weeks<br/> 18.75 mg for four weeks<br/> 25 mg for four weeks<br/> 37.5 mg for four weeks<br/> 50 mg for four weeks<br/> 75 mg for four weeks<br/> 100 mg for four weeks</td>
<td align="left" colspan="2" rowspan="1" valign="top">Exposure to multiple serotonergic agents has inherent risks<br/>Potential for cytochrome P450– mediated drug reactions depending on drug choice<br/>Increased pill burden and financial strain for patients</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Direct switch</td>
<td align="left" colspan="1" rowspan="1" valign="top">Start a new medication immediately after discontinuing the current one</td>
<td align="left" colspan="1" rowspan="1" valign="top">Discontinue citalopram, 20 mg</td>
<td align="left" colspan="1" rowspan="1" valign="top">Initiate sertraline, 50 mg</td>
<td align="left" colspan="2" rowspan="1" valign="top">May be difficult to determine if patient-reported adverse effects are due to the new agent or antidepressant discontinuation syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Moderate switch</td>
<td align="left" colspan="1" rowspan="1" valign="top">Current medication is tapered down, followed by a washout period of two or three days<br/>New medication is initiated at a conservative dose, then increased</td>
<td align="left" colspan="2" rowspan="1" valign="top">Citalopram (current medication):<br/> 20 mg for four weeks<br/> 15 mg for four weeks<br/> 10 mg for four weeks<br/> 7.5 mg for four weeks<br/> 5 mg for four weeks<br/> 2.5 mg for four weeks<br/>Discontinue for two- to three-day washout period<br/>Start sertraline:<br/> 25 mg for four weeks<br/> 37.5 mg for four weeks<br/> 50 mg for four weeks</td>
<td align="left" colspan="1" rowspan="1" valign="top">Potential for antidepressant discontinuation syndrome due to drug-free period<br/>More time-consuming but considered to be safer</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Conservative switch</td>
<td align="left" colspan="1" rowspan="1" valign="top">Current medication is tapered down, followed by a washout period of four or five half-lives<br/>New medication is initiated at a conservative dose, then increased</td>
<td align="left" colspan="2" rowspan="1" valign="top">Same as moderate switch but with longer washout period (seven days for most drugs, except those with long half-lives [e.g., fluoxetine])</td>
<td align="left" colspan="1" rowspan="1" valign="top">Potential for antidepressant discontinuation syndrome due to drug-free period<br/>Patients must wait longer for treatment benefit from new medication</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<italic toggle="yes">Information from references <sup>
<xref ref-type="bibr" rid="afp20230200p173-b51">51</xref>
</sup>–<sup>
<xref ref-type="bibr" rid="afp20230200p173-b53">53</xref>
</sup>
</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>
<h2>Special Populations</h2>
</p>
<p>
<h3>PREGNANT PATIENTS</h3>
</p>
<p>Approximately 12% of patients in the perinatal period meet criteria for major depressive disorder.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b57">57</xref>
</sup> Patients with untreated depression during pregnancy have a higher incidence of preterm birth and low-birth-weight infants compared with those without depression.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b58">58</xref>
</sup> Treatment of depression has not been shown to improve these outcomes, and SSRIs may be independently associated with preterm birth.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b59">59</xref>,<xref ref-type="bibr" rid="afp20230200p173-b60">60</xref>
</sup> </p>
<p>
<span id="afp20230200p173-sort5">Screening pregnant and postpartum patients for depression is associated with a 2% to 9% reduction in absolute risk of depression at three to five months, with or without treatment.</span>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b61">61</xref>
</sup> The U.S. Preventive Services Task Force recommends that clinicians provide or refer pregnant and postpartum patients who are at increased risk of perinatal depression to counseling interventions.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b62">62</xref>
</sup>
</p>
<p>For patients taking antidepressants before pregnancy, discontinuation is more likely to lead to relapse when depression is severe or recurrent. A meta-analysis showed that discontinuation of antidepressants in patients with mild to moderate depression is not significantly associated with relapse.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b63">63</xref>
</sup> Patients should continue their antidepressant when, through shared decision-making, the risk of relapse is determined to be greater than the risk of rare neonatal complications.</p>
<p>Cohort studies have inconsistently shown a small correlation between first-trimester SSRI use and cardiac malformations (RR = 1.24; 95% CI, 1.11 to 1.37).<sup>
<xref ref-type="bibr" rid="afp20230200p173-b64">64</xref>–<xref ref-type="bibr" rid="afp20230200p173-b66">66</xref>
</sup> SSRI use during the third trimester may increase the risk of newborn respiratory distress, tremors, and admission to the neonatal intensive care unit.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b67">67</xref>–<xref ref-type="bibr" rid="afp20230200p173-b69">69</xref>
</sup> Discontinuation of SSRIs in the third trimester does not improve these outcomes.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b70">70</xref>
</sup> There are no data on long-term neurocognitive effects.</p>
<p>A U.S. Food and Drug Administration advisory on SSRI use during pregnancy and the risk of persistent pulmonary hypertension in newborns cites conflicting findings; a causal relationship is unclear.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b71">71</xref>
</sup> A systematic review and meta-analysis found a slightly increased risk of persistent pulmonary hypertension in newborns with prenatal exposure to SSRIs and SNRIs (number needed to harm = 1,000).<sup>
<xref ref-type="bibr" rid="afp20230200p173-b72">72</xref>
</sup>
</p>
<p>
<h3>BREASTFEEDING PATIENTS</h3>
</p>
<p>Antidepressants transfer into breast milk in low concentrations. This transfer is thought to be lower for paroxetine and sertraline than other antidepressants, producing undetectable concentrations in infant plasma. Fluoxetine and venlafaxine produce the highest infant plasma concentrations. Potential adverse effects in infants exposed to SSRIs via breast milk have been documented only in case reports, most commonly with fluoxetine and citalopram. The effects are nonspecific and include irritability and decreased feeding. Overall, there is little evidence to support a causal link between antidepressant use in breastfeeding patients and adverse effects in their infants.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b73">73</xref>
</sup> </p>
<p>
<h3>OLDER ADULTS</h3>
</p>
<p>Approximately 50% of patients older than 65 years who have depression report at least a 50% improvement in symptoms with antidepressant use.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b74">74</xref>
</sup> Although prior studies showed no difference in the effectiveness of antidepressants in older patients, a 2019 network meta-analysis found that response rates are significantly higher with quetiapine (RR = 2.09) and duloxetine (RR = 1.83) in this population compared with placebo.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b75">75</xref>
</sup> Quetiapine includes a U.S. Food and Drug Administration boxed warning due to increased mortality risk in older patients with dementia-related psychosis. Some drugs are associated with higher rates of remission compared with placebo: quetiapine (RR = 2.38), mirtazapine (RR = 1.90), and duloxetine (RR = 1.52). In older patients, fall risk should be evaluated and steps taken to mitigate the risk because untreated depression and antidepressant use can both contribute to falls.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b76">76</xref>
</sup> </p>
<p>Because older adults are at greater risk of adverse drug reactions, initiating treatment at approximately one-half of the usual adult starting dose is often recommended. <span id="afp20230200p173-sort6B">Guidelines recommend sertraline, duloxetine, or escitalopram as good first-line options for older patients.</span>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b77">77</xref>
</sup> Bupropion, mirtazapine, and venlafaxine are also considered appropriate because of their favorable side effect profiles. <span id="afp20230200p173-sort6A">Paroxetine is associated with more anticholinergic effects, and fluoxetine has a greater risk of agitation and overstimulation; neither should be used in older adults.</span>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b77">77</xref>
</sup> Before initiating SSRIs and SNRIs in older adults, clinicians should screen for a history of hyponatremia and measure serum sodium level two to four weeks after initiating therapy.<sup>
<xref ref-type="bibr" rid="afp20230200p173-b77">77</xref>
</sup>
</p>
<p>This article updates previous articles on this topic by <uri xlink:href="https://www.aafp.org/pubs/afp/issues/2015/0715/p94.html">Kovich and DeJong</uri>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b78">78</xref>
</sup>; <uri xlink:href="https://www.aafp.org/pubs/afp/issues/2008/0315/p785.html">Adams, et al.</uri>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b79">79</xref>
</sup>; and <uri xlink:href="https://www.aafp.org/pubs/afp/issues/2006/0801/p449.html">Warner, et al.</uri>
<sup>
<xref ref-type="bibr" rid="afp20230200p173-b80">80</xref>
</sup>
</p>
<p>
<bold>Data Sources: </bold>PubMed searches were completed using key terms such as depression, antidepressant, and antidepressant discontinuation and specific classes of antidepressant medications (e.g., selective serotonin reuptake inhibitor). Additional terms were added to further refine results. For example, after an initial search generated a list of common antidepressant adverse effects, each effect was searched separately. The search included meta-analyses, randomized controlled trials, systematic reviews, and clinical trials. The U.S. Preventive Services Task Force recommendations were referenced, and citations from relevant recommendations were examined. Essential Evidence Plus and the Cochrane database were also searched. Search dates: February through December 2022.</p>
</body>
<back>
<fn-group>
<fn id="afp20230200p173-fn5">
<p>This article updates previous articles on this topic by Kovich and DeJong<xref ref-type="bibr" rid="afp20230200p173-b78">78</xref>; Adams, et al.<xref ref-type="bibr" rid="afp20230200p173-b79">79</xref>; and Warner, et al.<xref ref-type="bibr" rid="afp20230200p173-b80">80</xref>
</p>
</fn>
<fn id="afp20230200p173-fn6">
<p>
<bold>Data Sources:</bold> PubMed searches were completed using key terms such as depression, antidepressant, and antidepressant discontinuation and specific classes of antidepressant medications (e.g., selective serotonin reuptake inhibitor). Additional terms were added to further refine results. For example, after an initial search generated a list of common antidepressant adverse effects, each effect was searched separately. The search included meta-analyses, randomized controlled trials, systematic reviews, and clinical trials. The U.S. Preventive Services Task Force recommendations were referenced, and citations from relevant recommendations were examined. Essential Evidence Plus and the Cochrane database were also searched. Search dates: February through December 2022.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="afp20230200p173-b1">
<label>1</label>
<mixed-citation publication-type="web">U.S. Department of Health and Human Services. National Centers for Health Statistics. Health, United States, 2013: with special feature on prescription drugs. Accessed April 21, 2022. <uri xlink:href="http://www.cdc.gov/nchs/data/hus/hus13.pdf">http://www.cdc.gov/nchs/data/hus/hus13.pdf</uri>
</mixed-citation>
</ref>
<ref id="afp20230200p173-b2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Brody</surname>
<given-names>DJ</given-names>
</name>
<name name-style="western">
<surname>Gu</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Antidepressant use among adults: United States, 2015–2018</article-title>. <source>NCHS Data Brief</source>
<year>2020</year>; (<issue>377</issue>):<fpage>1</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Martin</surname>
<given-names>CB</given-names>
</name>
<name name-style="western">
<surname>Hales</surname>
<given-names>CM</given-names>
</name>
<name name-style="western">
<surname>Gu</surname>
<given-names>Q</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Prescription drug use in the United States, 2015–2016</article-title>. <source>NCHS Data Brief</source>
<year>2019</year>; (<issue>334</issue>): <fpage>1</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Twenge</surname>
<given-names>JM</given-names>
</name>
<name name-style="western">
<surname>Cooper</surname>
<given-names>AB</given-names>
</name>
<name name-style="western">
<surname>Joiner</surname>
<given-names>TE</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Age, period, and cohort trends in mood disorder indicators and suicide-related outcomes in a nationally representative dataset, 2005–2017</article-title>. <source>J Abnorm Psychol</source>
<year>2019</year>; <volume>128</volume>(<issue>3</issue>): <fpage>185</fpage>–<lpage>199</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Hedegaard</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Curtin</surname>
<given-names>SC</given-names>
</name>
<name name-style="western">
<surname>Warner</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Suicide mortality in the United States, 1999–2019</article-title>. <source>NCHS Data Brief</source>
<year>2021</year>; (<issue>398</issue>): <fpage>1</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b6">
<label>6</label>
<mixed-citation publication-type="web">U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health. 2020 NSDUH detailed tables. January 11, 2022. Accessed April 21, 2022. <uri xlink:href="https://www.samhsa.gov/data/report/2020-nsduh-detailed-tables">https://www.samhsa.gov/data/report/2020-nsduh-detailed-tables</uri>
</mixed-citation>
</ref>
<ref id="afp20230200p173-b7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Weinberger</surname>
<given-names>AH</given-names>
</name>
<name name-style="western">
<surname>Gbedemah</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Martinez</surname>
<given-names>AM</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Trends in depression prevalence in the USA from 2005 to 2015: widening disparities in vulnerable groups</article-title>. <source>Psychol Med</source>
<year>2018</year>; <volume>48</volume>(<issue>8</issue>): <fpage>1308</fpage>–<lpage>1315</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b8">
<label>8</label>
<mixed-citation publication-type="book">
<italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders</italic>. 5th ed. American Psychiatric Association; 2014.</mixed-citation>
</ref>
<ref id="afp20230200p173-b9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Mojtabai</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Clinician-identified depression in community settings: concordance with structured-interview diagnoses</article-title>. <source>Psychother Psychosom</source>
<year>2013</year>; <volume>82</volume>(<issue>3</issue>): <fpage>161</fpage>–<lpage>169</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Qaseem</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Barry</surname>
<given-names>MJ</given-names>
</name>
<name name-style="western">
<surname>Kansagara</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians</article-title>. <source>Ann Intern Med</source>
<year>2016</year>; <volume>164</volume>(<issue>5</issue>): <fpage>350</fpage>–<lpage>359</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Arroll</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Chin</surname>
<given-names>WY</given-names>
</name>
<name name-style="western">
<surname>Martis</surname>
<given-names>W</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressants for treatment of depression in primary care: a systematic review and meta-analysis</article-title>. <source>J Prim Health Care</source>
<year>2016</year>; <volume>8</volume>(<issue>4</issue>): <fpage>325</fpage>–<lpage>334</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Cipriani</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Furukawa</surname>
<given-names>TA</given-names>
</name>
<name name-style="western">
<surname>Salanti</surname>
<given-names>G</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis</article-title>. <source>Lancet</source>
<year>2018</year>; <volume>391</volume>(<issue>10128</issue>): <fpage>1357</fpage>–<lpage>1366</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b13">
<label>13</label>
<mixed-citation publication-type="other">Stone M, Kalaria S, Richardville K, et al. Components and trends in treatment effects in randomized placebo-controlled trials in major depressive disorder from 1979–2016. Poster presented at: American Society of Clinical Psychopharmacology Annual Conference; May 2018; Miami, FL.</mixed-citation>
</ref>
<ref id="afp20230200p173-b14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Turner</surname>
<given-names>EH</given-names>
</name>
<name name-style="western">
<surname>Cipriani</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Furukawa</surname>
<given-names>TA</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Selective publication of anti-depressant trials and its influence on apparent efficacy: updated comparisons and meta-analyses of newer versus older trials</article-title>. <source>PLoS Med</source>
<year>2022</year>; <volume>19</volume>(<issue>1</issue>): <fpage>e1003886</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Almohammed</surname>
<given-names>OA</given-names>
</name>
<name name-style="western">
<surname>Alsalem</surname>
<given-names>AA</given-names>
</name>
<name name-style="western">
<surname>Almangour</surname>
<given-names>AA</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressants and health-related quality of life (HRQoL) for patients with depression: analysis of the medical expenditure panel survey from the United States</article-title>. <source>PLoS One</source>
<year>2022</year>; <volume>17</volume>(<issue>4</issue>): <fpage>e0265928</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b16">
<label>16</label>
<mixed-citation publication-type="web">American Psychological Association. Clinical practice guideline for the treatment of depression across three age cohorts. February 2019. Accessed April 21, 2022. <uri xlink:href="https://www.apa.org/depression-guideline">https://www.apa.org/depression-guideline</uri>
</mixed-citation>
</ref>
<ref id="afp20230200p173-b17">
<label>17</label>
<mixed-citation publication-type="web">National Institute for Health and Care Excellence. Depression in adults: treatment and management. June 29, 2022. Accessed August 12, 2022. <uri xlink:href="https://www.nice.org.uk/guidance/ng222">https://www.nice.org.uk/guidance/ng222</uri>
</mixed-citation>
</ref>
<ref id="afp20230200p173-b18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Cuijpers</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Oud</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Karyotaki</surname>
<given-names>E</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Psychologic treatment of depression compared with pharmacotherapy and combined treatment in primary care: a network meta-analysis</article-title>. <source>Ann Fam Med</source>
<year>2021</year>; <volume>19</volume>(<issue>3</issue>): <fpage>262</fpage>–<lpage>270</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Cuijpers</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Noma</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Karyotaki</surname>
<given-names>E</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression</article-title>. <source>World Psychiatry</source>
<year>2020</year>; <volume>19</volume>(<issue>1</issue>): <fpage>92</fpage>–<lpage>107</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Guidi</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Fava</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder: a systematic review and meta-analysis</article-title>. <source>JAMA Psychiatry</source>
<year>2021</year>; <volume>78</volume>(<issue>3</issue>): <fpage>261</fpage>–<lpage>269</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b21">
<label>21</label>
<mixed-citation publication-type="web">Li KX, Loshak H. Pharmacogenomic testing in depression: a review of clinical effectiveness, cost-effectiveness, and guidelines. Canadian Agency for Drugs and Technologies in Health. January 31, 2020. Updated February 18, 2020. Accessed December 5, 2022. <uri xlink:href="https://www.cadth.ca/pharmacogenomic-testing-depression-review-clinical-effectiveness-cost-effectiveness-and-guidelines">https://www.cadth.ca/pharmacogenomic-testing-depression-review-clinical-effectiveness-cost-effectiveness-and-guidelines</uri>
</mixed-citation>
</ref>
<ref id="afp20230200p173-b22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Gartlehner</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Gaynes</surname>
<given-names>BN</given-names>
</name>
<name name-style="western">
<surname>Hansen</surname>
<given-names>RA</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians</article-title>. <source>Ann Intern Med</source>
<year>2008</year>; <volume>149</volume>(<issue>10</issue>): <fpage>734</fpage>–<lpage>750</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Alonso-Pedrero</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Bes-Rastrollo</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Marti</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Effects of antidepressant and antipsychotic use on weight gain: a systematic review</article-title>. <source>Obes Rev</source>
<year>2019</year>; <volume>20</volume>(<issue>12</issue>): <fpage>1680</fpage>–<lpage>1690</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Prasitlumkum</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Cheungpasitporn</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Tokavanich</surname>
<given-names>N</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressants and risk of sudden cardiac death: a network meta-analysis and systematic review</article-title>. <source>Med Sci (Basel)</source>
<year>2021</year>; <volume>9</volume>(<issue>2</issue>): <fpage>26</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Teply</surname>
<given-names>RM</given-names>
</name>
<name name-style="western">
<surname>Packard</surname>
<given-names>KA</given-names>
</name>
<name name-style="western">
<surname>White</surname>
<given-names>ND</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Treatment of depression in patients with concomitant cardiac disease</article-title>. <source>Prog Cardiovasc Dis</source>
<year>2016</year>; <volume>58</volume>(<issue>5</issue>): <fpage>514</fpage>–<lpage>528</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Coupland</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Hill</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Morriss</surname>
<given-names>R</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressant use and risk of adverse outcomes in people aged 20–64 years: cohort study using a primary care database</article-title>. <source>BMC Med</source>
<year>2018</year>; <volume>16</volume>(<issue>1</issue>): <fpage>36</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Jiang</surname>
<given-names>HY</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>HZ</given-names>
</name>
<name name-style="western">
<surname>Hu</surname>
<given-names>XJ</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2015</year>; <volume>13</volume>(<issue>1</issue>): <fpage>42</fpage>–<lpage>50.e3</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Voican</surname>
<given-names>CS</given-names>
</name>
<name name-style="western">
<surname>Corruble</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Naveau</surname>
<given-names>S</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressant-induced liver injury: a review for clinicians</article-title>. <source>Am J Psychiatry</source>
<year>2014</year>; <volume>171</volume>(<issue>4</issue>): <fpage>404</fpage>–<lpage>415</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>De Picker</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Van Den Eede</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Dumont</surname>
<given-names>G</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressants and the risk of hyponatremia: a class-by-class review of literature</article-title>. <source>Psychosomatics</source>
<year>2014</year>; <volume>55</volume>(<issue>6</issue>): <fpage>536</fpage>–<lpage>547</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Moura</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Bernatsky</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Abrahamowicz</surname>
<given-names>M</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS)</article-title>. <source>Osteoporos Int</source>
<year>2014</year>; <volume>25</volume>(<issue>5</issue>): <fpage>1473</fpage>–<lpage>1481</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b31">
<label>31</label>
<mixed-citation publication-type="web">U.S. Food and Drug Administration drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. March 28, 2012. Accessed April 21, 2022. <uri xlink:href="https://www.fda.gov/Drugs/DrugSafety/ucm297391.htm">https://www.fda.gov/Drugs/DrugSafety/ucm297391.htm</uri>
</mixed-citation>
</ref>
<ref id="afp20230200p173-b32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Castro</surname>
<given-names>VM</given-names>
</name>
<name name-style="western">
<surname>Clements</surname>
<given-names>CC</given-names>
</name>
<name name-style="western">
<surname>Murphy</surname>
<given-names>SN</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>QT interval and antidepressant use: a cross sectional study of electronic health records</article-title>. <source>BMJ</source>
<year>2013</year>; <volume>346</volume>: <fpage>f288</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Reichenpfader</surname>
<given-names>U</given-names>
</name>
<name name-style="western">
<surname>Gartlehner</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Morgan</surname>
<given-names>LC</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis</article-title>. <source>Drug Saf</source>
<year>2014</year>; <volume>37</volume>(<issue>1</issue>): <fpage>19</fpage>–<lpage>31</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Worthington JJ</surname>
<given-names>III</given-names>
</name>
<name name-style="western">
<surname>Peters</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>Treatment of antidepressant-induced sexual dysfunction</article-title>. <source>Drugs Today (Barc)</source>
<year>2003</year>; <volume>39</volume>(<issue>11</issue>): <fpage>887</fpage>–<lpage>896</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Sharma</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Guski</surname>
<given-names>LS</given-names>
</name>
<name name-style="western">
<surname>Freund</surname>
<given-names>N</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports</article-title>. <source>BMJ</source>
<year>2016</year>; <volume>352</volume>: <fpage>i65</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Gafoor</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Booth</surname>
<given-names>HP</given-names>
</name>
<name name-style="western">
<surname>Gulliford</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study</article-title>. <source>BMJ</source>
<year>2018</year>; <volume>361</volume>: <fpage>k1951</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b37">
<label>37</label>
<mixed-citation publication-type="web">Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. Third edition. American Psychiatric Association. October 2010. Accessed August 10, 2022. <uri xlink:href="https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf">https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf</uri>
</mixed-citation>
</ref>
<ref id="afp20230200p173-b38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Jung</surname>
<given-names>WY</given-names>
</name>
<name name-style="western">
<surname>Jang</surname>
<given-names>SH</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>SG</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Times to discontinue antidepressants over 6 months in patients with major depressive disorder</article-title>. <source>Psychiatry Investig</source>
<year>2016</year>; <volume>13</volume>(<issue>4</issue>): <fpage>440</fpage>–<lpage>446</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>McCrea</surname>
<given-names>RL</given-names>
</name>
<name name-style="western">
<surname>Sammon</surname>
<given-names>CJ</given-names>
</name>
<name name-style="western">
<surname>Nazareth</surname>
<given-names>I</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Initiation and duration of selective serotonin reuptake inhibitor prescribing over time: UK cohort study</article-title>. <source>Br J Psychiatry</source>
<year>2016</year>; <volume>209</volume>(<issue>5</issue>): <fpage>421</fpage>–<lpage>426</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Sinclair</surname>
<given-names>JE</given-names>
</name>
<name name-style="western">
<surname>Aucott</surname>
<given-names>LS</given-names>
</name>
<name name-style="western">
<surname>Lawton</surname>
<given-names>K</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>The monitoring of longer term prescriptions of antidepressants: observational study in a primary care setting</article-title>. <source>Fam Pract</source>
<year>2014</year>; <volume>31</volume>(<issue>4</issue>): <fpage>419</fpage>–<lpage>426</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Sim</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Lau</surname>
<given-names>WK</given-names>
</name>
<name name-style="western">
<surname>Sim</surname>
<given-names>J</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials [published correction appears in <italic toggle="yes">Int J Neuropsychopharmacol</italic>. 2016; 19(10); pyw031]</article-title>. <source>Int J Neuropsychopharmacol</source>
<year>2015</year>; <volume>19</volume>(<issue>2</issue>): <fpage>pyv076</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Lewis</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Marston</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Duffy</surname>
<given-names>L</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Maintenance or discontinuation of antidepressants in primary care</article-title>. <source>N Engl J Med</source>
<year>2021</year>; <volume>385</volume>(<issue>14</issue>): <fpage>1257</fpage>–<lpage>1267</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Machmutow</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Meister</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Jansen</surname>
<given-names>A</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2019</year>; (<issue>5</issue>): <fpage>CD012855</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</name>
<name name-style="western">
<surname>Lau</surname>
<given-names>WK</given-names>
</name>
<name name-style="western">
<surname>Sim</surname>
<given-names>J</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Duration of initial antidepressant treatment and subsequent relapse of major depression</article-title>. <source>J Clin Psychopharmacol</source>
<year>2015</year>; <volume>35</volume>(<issue>1</issue>): <fpage>75</fpage>–<lpage>76</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Kennedy</surname>
<given-names>SH</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>RW</given-names>
</name>
<name name-style="western">
<surname>McIntyre</surname>
<given-names>RS</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments [published correction appears in <italic toggle="yes">Can J Psychiatry</italic>. 2017; 62(5): 356]</article-title>. <source>Can J Psychiatry</source>
<year>2016</year>; <volume>61</volume>(<issue>9</issue>): <fpage>540</fpage>–<lpage>560</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Davies</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Read</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based?</article-title> <source>Addict Behav</source>
<year>2019</year>; <volume>97</volume>: <fpage>111</fpage>–<lpage>121</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Bhat</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Kennedy</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Recognition and management of antidepressant discontinuation syndrome</article-title>. <source>J Psychiatry Neurosci</source>
<year>2017</year>; <volume>42</volume>(<issue>4</issue>): <fpage>E7</fpage>–<lpage>E8</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Horowitz</surname>
<given-names>MA</given-names>
</name>
<name name-style="western">
<surname>Taylor</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Tapering of SSRI treatment to mitigate withdrawal symptoms</article-title>. <source>Lancet Psychiatry</source>
<year>2019</year>; <volume>6</volume>(<issue>6</issue>): <fpage>538</fpage>–<lpage>546</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Henssler</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Heinz</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Brandt</surname>
<given-names>L</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressant withdrawal and rebound phenomena</article-title>. <source>Dtsch Arztebl Int</source>
<year>2019</year>; <volume>116</volume>(<issue>20</issue>): <fpage>355</fpage>–<lpage>361</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Zwiebel</surname>
<given-names>SJ</given-names>
</name>
<name name-style="western">
<surname>Viguera</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Discontinuing antidepressants: pearls and pitfalls</article-title>. <source>Cleve Clin J Med</source>
<year>2022</year>; <volume>89</volume>(<issue>1</issue>): <fpage>18</fpage>–<lpage>26</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Fava</surname>
<given-names>GA</given-names>
</name>
<name name-style="western">
<surname>Benasi</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Lucente</surname>
<given-names>M</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review</article-title>. <source>Psychother Psychosom</source>
<year>2018</year>; <volume>87</volume>(<issue>4</issue>): <fpage>195</fpage>–<lpage>203</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Tint</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Haddad</surname>
<given-names>PM</given-names>
</name>
<name name-style="western">
<surname>Anderson</surname>
<given-names>IM</given-names>
</name>
</person-group>
<article-title>The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study [published correction appears in <italic toggle="yes">J Psychopharmacol</italic>. 2009; 23(8): 1006]</article-title>. <source>J Psychopharmacol</source>
<year>2008</year>; <volume>22</volume>(<issue>3</issue>): <fpage>330</fpage>–<lpage>332</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Phelps</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Tapering antidepressants: is 3 months slow enough?</article-title> <source>Med Hypotheses</source>
<year>2011</year>; <volume>77</volume>(<issue>6</issue>): <fpage>1006</fpage>–<lpage>1008</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Jefferson</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Strategies for switching antidepressants to achieve maximum efficacy</article-title>. <source>J Clin Psychiatry</source>
<year>2008</year>; <volume>69</volume>(<issue>suppl E1</issue>): <fpage>14</fpage>–<lpage>18</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Himei</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Okamura</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome</article-title>. <source>CNS Drugs</source>
<year>2006</year>; <volume>20</volume>(<issue>8</issue>): <fpage>665</fpage>–<lpage>672</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Maund</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Stuart</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Moore</surname>
<given-names>M</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Managing antidepressant discontinuation: a systematic review</article-title>. <source>Ann Fam Med</source>
<year>2019</year>; <volume>17</volume>(<issue>1</issue>): <fpage>52</fpage>–<lpage>60</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Woody</surname>
<given-names>CA</given-names>
</name>
<name name-style="western">
<surname>Ferrari</surname>
<given-names>AJ</given-names>
</name>
<name name-style="western">
<surname>Siskind</surname>
<given-names>DJ</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>A systematic review and meta-regression of the prevalence and incidence of perinatal depression</article-title>. <source>J Affect Disord</source>
<year>2017</year>; <volume>219</volume>: <fpage>86</fpage>–<lpage>92</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Jarde</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Morais</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Kingston</surname>
<given-names>D</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Neonatal outcomes in women with untreated antenatal depression compared with women without depression: a systematic review and meta-analysis</article-title>. <source>JAMA Psychiatry</source>
<year>2016</year>; <volume>73</volume>(<issue>8</issue>): <fpage>826</fpage>–<lpage>837</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Eke</surname>
<given-names>AC</given-names>
</name>
<name name-style="western">
<surname>Saccone</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Berghella</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis</article-title>. <source>BJOG</source>
<year>2016</year>; <volume>123</volume>(<issue>12</issue>): <fpage>1900</fpage>–<lpage>1907</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Vlenterie</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>van Gelder</surname>
<given-names>MMHJ</given-names>
</name>
<name name-style="western">
<surname>Anderson</surname>
<given-names>HR</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Associations between maternal depression, antidepressant use during pregnancy, and adverse pregnancy outcomes: an individual participant data meta-analysis</article-title>. <source>Obstet Gynecol</source>
<year>2021</year>; <volume>138</volume>(<issue>4</issue>): <fpage>633</fpage>–<lpage>646</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>O'Connor</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Rossom</surname>
<given-names>RC</given-names>
</name>
<name name-style="western">
<surname>Henninger</surname>
<given-names>M</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Primary care screening for and treatment of depression in pregnant and postpartum women: evidence report and systematic review for the US Preventive Services Task Force</article-title>. <source>JAMA</source>
<year>2016</year>; <volume>315</volume>(<issue>4</issue>): <fpage>388</fpage>–<lpage>406</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Curry</surname>
<given-names>SJ</given-names>
</name>
<name name-style="western">
<surname>Krist</surname>
<given-names>AH</given-names>
</name>
<name name-style="western">
<surname>Owens</surname>
<given-names>DK</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Interventions to prevent perinatal depression: US Preventive Services Task Force recommendation statement</article-title>. <source>JAMA</source>
<year>2019</year>; <volume>321</volume>(<issue>6</issue>): <fpage>580</fpage>–<lpage>587</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Bayrampour</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Kapoor</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Bunka</surname>
<given-names>M</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>The risk of relapse of depression during pregnancy af ter discontinuation of antidepressants: a systematic review and meta-analysis</article-title>. <source>J Clin Psychiatry</source>
<year>2020</year>; <volume>81</volume>(<issue>4</issue>): <fpage>19r13134</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Huybrechts</surname>
<given-names>KF</given-names>
</name>
<name name-style="western">
<surname>Palmsten</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Avorn</surname>
<given-names>J</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressant use in pregnancy and the risk of cardiac defects</article-title>. <source>N Engl J Med</source>
<year>2014</year>; <volume>370</volume>(<issue>25</issue>): <fpage>2397</fpage>–<lpage>2407</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Bérard</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Zhao</surname>
<given-names>JP</given-names>
</name>
<name name-style="western">
<surname>Sheehy</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort</article-title>. <source>BMJ Open</source>
<year>2017</year>; <volume>7</volume>(<issue>1</issue>): <fpage>e013372</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Gao</surname>
<given-names>SY</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>QJ</given-names>
</name>
<name name-style="western">
<surname>Sun</surname>
<given-names>C</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births</article-title>. <source>BMC Med</source>
<year>2018</year>; <volume>16</volume>(<issue>1</issue>): <fpage>205</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>McDonagh</surname>
<given-names>MS</given-names>
</name>
<name name-style="western">
<surname>Matthews</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Phillipi</surname>
<given-names>C</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Depression drug treatment outcomes in pregnancy and the postpartum period: a systematic review and meta-analysis</article-title>. <source>Obstet Gynecol</source>
<year>2014</year>; <volume>124</volume>(<issue>3</issue>): <fpage>526</fpage>–<lpage>534</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Grigoriadis</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>VonderPorten</surname>
<given-names>EH</given-names>
</name>
<name name-style="western">
<surname>Mamisashvili</surname>
<given-names>L</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis</article-title>. <source>J Clin Psychiatry</source>
<year>2013</year>; <volume>74</volume>(<issue>4</issue>): <fpage>e309</fpage>–<lpage>e320</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Nörby</surname>
<given-names>U</given-names>
</name>
<name name-style="western">
<surname>Forsberg</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Wide</surname>
<given-names>K</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Neonatal morbidity after maternal use of antidepressant drugs during pregnancy</article-title>. <source>Pediatrics</source>
<year>2016</year>; <volume>138</volume>(<issue>5</issue>): <fpage>e20160181</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Warburton</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Hertzman</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Oberlander</surname>
<given-names>TF</given-names>
</name>
</person-group>
<article-title>A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health</article-title>. <source>Acta Psychiatr Scand</source>
<year>2010</year>; <volume>121</volume>(<issue>6</issue>): <fpage>471</fpage>–<lpage>479</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b71">
<label>71</label>
<mixed-citation publication-type="web">U.S. Food and Drug Administration. FDA Drug Safety Communication: selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. December 14, 2011. Accessed April 27, 2022. <uri xlink:href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-selective-serotonin-reuptake-inhibitor-ssri-antidepressant-use-during">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-selective-serotonin-reuptake-inhibitor-ssri-antidepressant-use-during</uri>
</mixed-citation>
</ref>
<ref id="afp20230200p173-b72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Masarwa</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Bar-Oz</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Gorelik</surname>
<given-names>E</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis</article-title>. <source>Am J Obstet Gynecol</source>
<year>2019</year>; <volume>220</volume>(<issue>1</issue>): <fpage>57.e1</fpage>–<lpage>57.e13</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Schoretsanitis</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Augustin</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Saßmannshausen</surname>
<given-names>H</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressants in breast milk; comparative analysis of excretion ratios</article-title>. <source>Arch Womens Ment Health</source>
<year>2019</year>; <volume>22</volume>(<issue>3</issue>): <fpage>383</fpage>–<lpage>390</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Gutsmiedl</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Krause</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Bighelli</surname>
<given-names>I</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis</article-title>. <source>BMC Psychiatry</source>
<year>2020</year>; <volume>20</volume>(<issue>1</issue>): <fpage>102</fpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Krause</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Gutsmiedl</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Bighelli</surname>
<given-names>I</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: a systematic review, pairwise and network meta-analysis</article-title>. <source>Eur Neuropsychopharmacol</source>
<year>2019</year>; <volume>29</volume>(<issue>9</issue>): <fpage>1003</fpage>–<lpage>1022</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>van Poelgeest</surname>
<given-names>EP</given-names>
</name>
<name name-style="western">
<surname>Pronk</surname>
<given-names>AC</given-names>
</name>
<name name-style="western">
<surname>Rhebergen</surname>
<given-names>D</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Depression, antidepressants and fall risk: therapeutic dilemmas—a clinical review</article-title>. <source>Eur Geriatr Med</source>
<year>2021</year>; <volume>12</volume>(<issue>3</issue>): <fpage>585</fpage>–<lpage>596</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b77">
<label>77</label>
<mixed-citation publication-type="web">Canadian Coalition for Seniors' Mental Health. Canadian guidelines on prevention, assessment and treatment of depression among older adults. Updated June 2021. Accessed August 13, 2022. <uri xlink:href="https://ccsmh.ca/wp-content/uploads/2021/06/CCSMH_Depression_Guidelines_FINAL_EN.pdf">https://ccsmh.ca/wp-content/uploads/2021/06/CCSMH_Depression_Guidelines_FINAL_EN.pdf</uri>
</mixed-citation>
</ref>
<ref id="afp20230200p173-b78">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Kovich</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>DeJong</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Common questions about the pharmacologic management of depression in adults</article-title>. <source>Am Fam Physician</source>
<year>2015</year>; <volume>92</volume>(<issue>2</issue>): <fpage>94</fpage>–<lpage>100</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b79">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Adams</surname>
<given-names>SM</given-names>
</name>
<name name-style="western">
<surname>Miller</surname>
<given-names>KE</given-names>
</name>
<name name-style="western">
<surname>Zylstra</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Pharmacologic management of adult depression</article-title>. <source>Am Fam Physician</source>
<year>2008</year>; <volume>77</volume>(<issue>6</issue>): <fpage>785</fpage>–<lpage>792</lpage>.</mixed-citation>
</ref>
<ref id="afp20230200p173-b80">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group>
<name name-style="western">
<surname>Warner</surname>
<given-names>CH</given-names>
</name>
<name name-style="western">
<surname>Bobo</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Warner</surname>
<given-names>C</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Antidepressant discontinuation syndrome</article-title>. <source>Am Fam Physician</source>
<year>2006</year>; <volume>74</volume>(<issue>3</issue>): <fpage>449</fpage>–<lpage>456</lpage>.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
